Best M-Spike in Four Years

Thursday, August 22, 2013,     Pomalyst Study Cycle 71: M-Spike was 0.9 g/dL this morning, compared with 1.1 last month. The last time that M-Spike was 0.9 or less was December, 2009, so we had a little celebration this morning. IgG was down as well, from 1290 mg/dL to 1100, although it has been at least that low three other times this year, so the combined results are definitely good news but probably not a breakthrough. Lambda and Kappa light chains were both just above the tops of their respective reference ranges. That seems to be a new normal for me - they're both slightly high. The ratio was fine. Magnesium: I have only a very little peripheral neuropathy, in the form of numbness and tingling of fingers and toes. No problem - most days I don't even think about it. However, I have regularly experienced painful muscle cramps, especially in the calves, most frequently at night or after a long run. Some people call this peripheral neuropathy but it's just muscle cramps, also known as charley horses. Since I started taking magnesium about a month ago in the form of magnesium taurate, 125 mg of elemental magnesium twice daily, I have not had one cramp, neither at night nor after a run. I've had one or two close calls, where I had to jump out of bed and stretch the calf to prevent an oncoming cramp, but no actual full-blown cramps. When I mentioned this to Dr TR, she confirmed that magnesium can be helpful in treating cramps. I got the impression, though,...
Source: Myeloma Hope - Category: Cancer Source Type: blogs

Related Links:

dante Most patients with multiple myeloma (MM) suffer from chronic pain at every stage of the natural disease process. This review focuses on the most common causes of chronic pain in MM patients: (1) pain from myeloma bone disease (MBD); (2) chemotherapy-induced peripheral neuropathy as a possible consequence of proteasome inhibitor therapy (i.e., bortezomib-induced); (3) post-herpetic neuralgia as a possible complication of varicella zoster virus reactivation because of post-transplantation immunodepression; and (4) pain in cancer survivors, with increasing numbers due to the success of antiblastic treatments, which ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Authors: Hus I, Mańko J, Jawniak D, Jurczyszyn A, Charliński G, Poniewierska-Jasak K, Usnarska-Zubkiewicz L, Sawicki M, Druzd-Sitek A, Świderska A, Kopińska A, Grząśko N, Raźny M, Wędłowska A, Perzyński A, Gałązka A, Dytfeld D, Kubicki T, Rodzaj M, Waszczuk-Gajda A, Drozd-Sokołowska J, Pogłódek B, Pasternak A, Długosz-Danecka M, Szymczyk A, Dmoszyńska A Abstract The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly-diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous ...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
CONCLUSION: There are a great number of nanoparticulate drug delivery systems for potential use in cancer therapy including non-targeted and targeted nanoparticles. Promising results to date using bortezomib nanoparticles for cancer treatment should lead to the implementation of further research with nanoparticulate-based drug delivery systems. PMID: 31692424 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
ConclusionThalidomide-based regimens are potential salvage treatment options for patients with RRMM, even with prior resistance to IMiDs.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
In this study, treatment-emergent neuropathy was assessed by total neuropathy score and electrophysiological examination. The expression level of TNF-α and HPSE were evaluated by enzyme-linked immunosorbent assay. The effects of anti-TNF-α on the evolution of neuropathy were tested in rat models of neurotoxicity. The results indicated that with the augment of cumulative dose of bortezomib, the incidence of neuropathy was increased. Moreover, bortezomib administration induced the expression of TNF-α. With the increased expression of TNF-α, neuropathy was exacerbated. TNF-α-induced expression of...
Source: Annals of Hematology - Category: Hematology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Sæmundur Rögnvaldsson, Vilhjálmur Steingrímsson, Ingemar Turesson, Magnus Björkholm, C. Ola Landgren, Sigurdur Kristinsson
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: October 2019Source: Clinical Lymphoma Myeloma and Leukemia, Volume 19, Issue 10, SupplementAuthor(s): Tiffany Li, Hannah Timmins, Tracy King, Matthew Kiernan, David Goldstein, Susanna Park
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: Determining the BDNF protein levels before initiating chemotherapy might be a useful tool for CIPN risk assessment and preemptive dose modification. The present data should be validated in larger studies that include other neurotoxic agents. PMID: 31591840 [PubMed]
Source: Journal of Clinical Neurology - Category: Neurology Tags: J Clin Neurol Source Type: research
by Drew Rosielle (@drosielle)A Series of Observations on Opioids By a Palliative Doc Who Prescribes A Lot of Opioids But Also Has Questions.This is the 5th post in a series about opioids, with a focus on how my thinking about opioids has changed over the years. See also:Part 1 – Introduction, General Disclaimers, Hand-Wringing, and a Hand-Crafted Graph.Part 2 – We Were Wrong 20 years Ago, Our Current Response to the Opioid Crisis is Wrong, But We Should Still Be Helping Most of our Long-Term Patients Reduce Their Opioid DosesPart 3 – Opioids Have Ceiling Effects, High-Doses are Rarely Therapeutic, and Ano...
Source: Pallimed: A Hospice and Palliative Medicine Blog - Category: Palliative Care Tags: cancer opioids pain rosielle The profession Source Type: blogs
Melphalan, prednisone and bortezomib (MPV) is a current standard in the treatment of transplant ineligible newly diagnosed multiple myeloma (TI NDMM) and has been used as a control arm in several recent phase 3 clinical trials. Bortezomib related peripheral neuropathy (PN) is a limiting factor to apply the original MPV dose and schedule and reduced intensity schedules have been used both in clinical practice and in clinical trials. However, the feasibility of full-dose MPV and the impact on efficacy of dose intensity in real world have not been described.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research
More News: Calcium | Magnesium | Men | Myeloma | Neurology | Peripheral Neuropathy | Study | Urology & Nephrology